Moderna’s Suit Against Pfizer/BioNTech Is About More Than Money

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Moderna is seeking financial compensation for Comirnaty in its patent infringement suit, but it seems especially keen to assert IP rights over what could become an even more valuable platform technology.

Moderna is filing a patent infringement suit against Pfizer/BioNTech over technology used in its Spikevax vaccine • Source: Shutterstock

Moderna, Inc. hasn’t disclosed how much it hopes Pfizer Inc. and BioNTech SE will pay if it wins its patent infringement suit accusing them of copying the messenger RNA (mRNA) technology it used to develop Spikevax in their own COVID-19 vaccine, Comirnaty. But it appears less interested in giving Spikevax a leg up on the market than in ensuring it maintains control over the underlying intellectual property fueling its rapidly expanding pipeline – as well as BioNTech’s.

Moderna announced on 26 August that it was filing patent infringement suits against Pfizer and BioNTech in the US District...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By Jung Won Shin

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip